ttx-mc138
·Code: TTX-MC138
ttx-mc138: developed by 1 company · 1 clinical trial tracked.
ttx-mc138 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect ttx-mc138 to RNAZ; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could ttx-mc138 → RNAZ affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Advanced Solid Tumor
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Transcode Therapeutics, Inc. (RNAZ) Advanced Solid Tumor | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1/2 Multicenter, Open-Label, Dose-escalation and Expansion Study of TTX-MC138 in Subjects With Advanced Solid Tumors
Primary endpoint: Dose Escalation - Adverse Events
Interventionalopen16 targetStarted 2024-09Completion 2027-024 sites · United StatesTransCode Therapeutics
Frequently asked questions
Who is developing ttx-mc138?
ttx-mc138 is being developed by Transcode Therapeutics, Inc..
How many clinical trials involve ttx-mc138?
BioSniper tracks 1 clinical trial involving ttx-mc138.